Globus Medical to Showcase SCRIPT™ Patient-Specific Implants and New XLIF™ Prone Procedural Solution at NASS 2026

AUDUBON, Pa., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced it will highlight its latest spine innovations at the 41st Annual North American Spine Society (NASS) Meeting in San Antonio, Texas, from October 14-17.

Globus Medical is continuing to expand its integrated spine ecosystem with technologies designed to connect patient-specific planning, implant solutions, and surgical execution across a range of spinal procedures. At NASS, the company will showcase SCRIPT™, its new patient-specific spinal implant platform, alongside the new XLIF™ Prone Procedural Solution featuring the XLIF™ Prone Patient Positioner and the MaXcess™ Air two-blade prone lateral retractor.

“We believe innovation is most meaningful when it connects technologies across the surgical workflow to support patient-specific planning and coordinated execution. Our focus is on developing an integrated ecosystem that helps surgeons translate their surgical plan in the operating room while supporting the clinical needs of each individual patient,” said Keith Pfeil, President and CEO.

SCRIPT™ marks Globus Medical’s expansion into patient-specific spine solutions. Within SCRIPT™ Studio, surgeons maintain control of preoperative planning and implant design, creating them while considering alignment, implant position, implant geometry, and fixation strategy. Plans generated from SCRIPT™ Studio can be imported into ExcelsiusGPS™ or ExcelsiusHub™ to integrate the preoperative plan with a navigated surgical workflow. SCRIPT™ will be featured in an exclusive preview at the Globus Medical technology suite, offering attendees an early look at this FDA-cleared technology as the company moves toward commercialization.

Globus Medical will also introduce the XLIF™ Prone Patient Positioner and MaXcess™ Air two-blade retractor as part of its XLIF™ Prone Procedural Solution. Bringing together patient positioning, lateral access, and enabling technologies, the solution is designed to support a connected workflow for prone lateral procedures. These new solutions combine adaptable patient positioning with stable, controlled lateral access to establish a reproducible workflow for prone lateral procedures. The XLIF™ Prone Patient Positioner allows adjustments in both the sagittal and coronal planes, while the MaXcess™ Air retractor provides a lightweight, rigid platform designed to support soft tissue management and stable access to the disc space.

Together, these technologies reflect Globus Medical’s continued investment in an integrated spine technology portfolio, connecting solutions across preoperative planning, patient-specific implants, procedural positioning, access, and surgical execution.

For more information on Globus Medical’s expanding spine portfolio, visit Globus Medical at NASS 2026, booth 315.

About Globus Medical, Inc.
Globus Medical, Inc. is a leading global musculoskeletal technology company dedicated to solving unmet clinical needs and changing lives. We innovate with inspired urgency, provide world-class education and clinical support, and advance care throughout spine, orthopedic trauma, joint reconstruction, biomaterials, and enabling technologies. Additional information can be accessed at www.globusmedical.com.

Safe Harbor Statements
All statements included in this press release other than statements of historical fact are forward-looking statements and may be identified by their use of words such as “believe,” “may,” “might,” “could,” “will,” “aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan” and other similar terms. These forward-looking statements are based on our current assumptions, expectations, and estimates of future events and trends. Forward-looking statements are only predictions and are subject to many risks, uncertainties, and other factors that may affect our businesses and operations and could cause actual results to differ materially from those predicted. These risks and uncertainties include, but are not limited to, the risks and costs associated with health epidemics, pandemics, and similar outbreaks, factors affecting our quarterly results, our ability to manage our growth, our ability to sustain our profitability, demand for our products, our ability to compete successfully (including without limitation our ability to convince surgeons to use our products and our ability to attract and retain sales and other personnel), our ability to rapidly develop and introduce new products, our ability to develop and execute on successful business strategies, our ability to comply with laws and regulations that are or may become applicable to our businesses, our ability to safeguard our intellectual property, our success in defending legal proceedings brought against us, trends in the medical device industry, general economic conditions, the successful integration of businesses that we have acquired or may acquire in the future, and other risks. For a discussion of these and other risks, uncertainties, and other factors that could affect our results, refer to the disclosures contained in our most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (the “SEC”), including the sections labeled “Risk Factors” and “Cautionary Note Concerning Forward-Looking Statements,” and in our subsequent filings with the SEC. These documents are available at www.sec.gov. Moreover, we operate in an evolving environment. New risk factors and uncertainties emerge from time to time and it is not possible for us to predict all risk factors and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements. Forward-looking statements contained in this press release speak only as of the date of this press release. Except as may be required by applicable law, we undertake no obligation to update any forward-looking statements as a result of new information, events or circumstances or other factors arising or coming to our attention after the date hereof. As used herein, the “Company,” “Globus”, “Globus Medical,” “we,” “us,” and “our” refers to Globus Medical, Inc.

Contact:

Shagun Singh
Senior Vice President, Strategy and Investor Relations
Phone: (610) 930-1800
Email: investors@globusmedical.com | www.globusmedical.com